These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 31711572)
21. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Nowakowska P; Romanski A; Miller N; Odendahl M; Bonig H; Zhang C; Seifried E; Wels WS; Tonn T Cancer Immunol Immunother; 2018 Jan; 67(1):25-38. PubMed ID: 28879551 [TBL] [Abstract][Full Text] [Related]
22. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173 [TBL] [Abstract][Full Text] [Related]
23. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731 [TBL] [Abstract][Full Text] [Related]
25. Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin. Zheng L; Wang H; Zhou J; Shi G; Ma J; Jiang Y; Dong Z; Li J; He YQ; Wu D; Sun J; Xu C; Li Z; Wang J J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964787 [TBL] [Abstract][Full Text] [Related]
26. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS Front Immunol; 2019; 10():2683. PubMed ID: 31798595 [TBL] [Abstract][Full Text] [Related]
27. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279 [TBL] [Abstract][Full Text] [Related]
28. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers. Pfeifer Serrahima J; Zhang C; Oberoi P; Bodden M; Röder J; Arndt C; Feldmann A; Kiefer A; Prüfer M; Kühnel I; Tonn T; Bachmann M; Wels WS Cancer Immunol Immunother; 2023 Sep; 72(9):2905-2918. PubMed ID: 36688995 [TBL] [Abstract][Full Text] [Related]
29. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. Batchu RB; Gruzdyn OV; Tavva PS; Kolli BK; Dachepalli R; Weaver DW; Gruber SA Surgery; 2019 Oct; 166(4):503-508. PubMed ID: 31416604 [TBL] [Abstract][Full Text] [Related]
30. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function. Mantesso S; Geerts D; Spanholtz J; Kučerová L Front Immunol; 2020; 11():607131. PubMed ID: 33391277 [TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Mehta RS; Rezvani K Front Immunol; 2018; 9():283. PubMed ID: 29497427 [TBL] [Abstract][Full Text] [Related]
32. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Hu W; Wang G; Huang D; Sui M; Xu Y Front Immunol; 2019; 10():1205. PubMed ID: 31214177 [TBL] [Abstract][Full Text] [Related]
33. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762 [TBL] [Abstract][Full Text] [Related]
34. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556 [TBL] [Abstract][Full Text] [Related]
36. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Daldrup-Link HE; Meier R; Rudelius M; Piontek G; Piert M; Metz S; Settles M; Uherek C; Wels W; Schlegel J; Rummeny EJ Eur Radiol; 2005 Jan; 15(1):4-13. PubMed ID: 15616814 [TBL] [Abstract][Full Text] [Related]
37. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer. Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264 [TBL] [Abstract][Full Text] [Related]
38. A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell. Li M; Zhi L; Yin M; Guo C; Zhang H; Lu C; Zhu W Biochem Biophys Res Commun; 2020 Mar; 523(3):745-752. PubMed ID: 31952789 [TBL] [Abstract][Full Text] [Related]
39. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477 [TBL] [Abstract][Full Text] [Related]
40. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]